Immunoprecise Non Current Liabilities Total vs Total Cash From Operating Activities Analysis
IPA Stock | USD 1.28 0.09 6.57% |
Immunoprecise Antibodies financial indicator trend analysis is infinitely more than just investigating Immunoprecise Antibodies recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunoprecise Antibodies is a good investment. Please check the relationship between Immunoprecise Antibodies Non Current Liabilities Total and its Total Cash From Operating Activities accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.
Non Current Liabilities Total vs Total Cash From Operating Activities
Non Current Liabilities Total vs Total Cash From Operating Activities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunoprecise Antibodies Non Current Liabilities Total account and Total Cash From Operating Activities. At this time, the significance of the direction appears to have pay attention.
The correlation between Immunoprecise Antibodies' Non Current Liabilities Total and Total Cash From Operating Activities is -0.96. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Total Cash From Operating Activities in the same time period over historical financial statements of Immunoprecise Antibodies, assuming nothing else is changed. The correlation between historical values of Immunoprecise Antibodies' Non Current Liabilities Total and Total Cash From Operating Activities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Immunoprecise Antibodies are associated (or correlated) with its Total Cash From Operating Activities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Cash From Operating Activities has no effect on the direction of Non Current Liabilities Total i.e., Immunoprecise Antibodies' Non Current Liabilities Total and Total Cash From Operating Activities go up and down completely randomly.
Correlation Coefficient | -0.96 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Non Current Liabilities Total
Total Cash From Operating Activities
Most indicators from Immunoprecise Antibodies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunoprecise Antibodies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.The current year's Selling General Administrative is expected to grow to about 23.9 M, whereas Tax Provision is projected to grow to (1 M).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 11.0M | 11.6M | 13.3M | 14.0M | Total Revenue | 19.4M | 20.7M | 23.8M | 25.0M |
Immunoprecise Antibodies fundamental ratios Correlations
Click cells to compare fundamentals
Immunoprecise Antibodies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunoprecise Antibodies fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 27.3M | 67.0M | 93.5M | 77.8M | 89.5M | 94.0M | |
Other Current Liab | 1.8M | 964K | 1.3M | 441K | 507.2K | 558.1K | |
Total Current Liabilities | 7.9M | 6.1M | 9.3M | 5.9M | 6.8M | 7.1M | |
Total Stockholder Equity | 15.1M | 56.9M | 75.3M | 57.8M | 66.5M | 69.8M | |
Property Plant And Equipment Net | 3.2M | 4.1M | 3.7M | 10.7M | 12.3M | 12.9M | |
Net Debt | 1.9M | (38.3M) | (27.4M) | (1.0M) | (911.7K) | (957.3K) | |
Retained Earnings | (22.5M) | (29.8M) | (46.5M) | (73.1M) | (65.8M) | (62.5M) | |
Accounts Payable | 1.8M | 3.0M | 4.8M | 3.4M | 3.9M | 4.1M | |
Cash | 2.6M | 41.8M | 30.0M | 8.3M | 9.5M | 10.0M | |
Non Current Assets Total | 19.6M | 18.1M | 56.0M | 61.0M | 70.2M | 73.7M | |
Cash And Short Term Investments | 2.6M | 41.8M | 30.0M | 8.3M | 9.5M | 10.0M | |
Net Receivables | 3.7M | 4.1M | 3.4M | 4.4M | 5.1M | 5.3M | |
Common Stock Shares Outstanding | 13.6M | 16.5M | 19.7M | 24.9M | 28.6M | 30.1M | |
Liabilities And Stockholders Equity | 27.3M | 67.0M | 93.5M | 77.8M | 89.5M | 94.0M | |
Other Current Assets | 614.0K | 2.3M | 2.8M | 2.6M | 3.0M | 3.1M | |
Other Stockholder Equity | 3.5M | 6.6M | 7.3M | 10.8M | 9.7M | 9.2M | |
Total Liab | 12.2M | 10.0M | 18.2M | 20.0M | 23.0M | 24.2M | |
Total Current Assets | 7.7M | 48.9M | 37.5M | 16.8M | 19.3M | 20.3M | |
Non Current Liabilities Total | 4.2M | 4.0M | 8.9M | 14.1M | 16.2M | 17.0M | |
Non Currrent Assets Other | 85.1K | 79K | 82K | 86K | 77.4K | 73.5K | |
Short Long Term Debt Total | 4.5M | 3.5M | 2.5M | 7.3M | 8.4M | 8.8M | |
Property Plant And Equipment Gross | 3.1M | 4.1M | 9.4M | 17.1M | 19.6M | 20.6M | |
Accumulated Other Comprehensive Income | (300.2K) | (687K) | (2.5M) | 2.6M | 2.4M | 2.5M | |
Short Term Debt | 2.9M | 986K | 2.2M | 1.1M | 1.3M | 888.8K | |
Inventory | 818.6K | 1.2M | 1.6M | 2.1M | 2.4M | 2.5M | |
Current Deferred Revenue | 1.5M | 1.1M | 1.0M | 977K | 1.1M | 567.8K | |
Intangible Assets | 8.3M | 6.1M | 32.4M | 30.9M | 35.6M | 37.3M | |
Common Stock | 34.1M | 80.1M | 114.6M | 117.5M | 135.1M | 141.8M | |
Net Tangible Assets | (1.0M) | 43.1M | 23.2M | 7.7M | 8.9M | 12.5M | |
Net Invested Capital | 17.7M | 58.5M | 76.6M | 57.8M | 66.5M | 39.4M | |
Net Working Capital | (230.3K) | 42.8M | 28.2M | 10.9M | 12.5M | 13.7M | |
Property Plant Equipment | 3.1M | 4.0M | 3.3M | 10.4M | 12.0M | 12.5M | |
Other Liab | 2.6M | 1.5M | 8.6M | 7.9M | 9.1M | 5.1M | |
Other Assets | 287.6K | 163K | 476K | 437K | 393.3K | 373.6K | |
Good Will | 7.9M | 7.8M | 19.7M | 19.2M | 22.0M | 12.4M | |
Capital Lease Obligations | 1.9M | 1.9M | 1.2M | 7.3M | 8.4M | 8.8M | |
Long Term Investments | 118.9K | 111K | 142K | 115K | 132.3K | 122.4K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Immunoprecise Stock analysis
When running Immunoprecise Antibodies' price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.42) | Revenue Per Share 0.939 | Quarterly Revenue Growth 0.203 | Return On Assets (0.11) | Return On Equity (0.26) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.